GlassScriptPhysician profile
James A Partridge
NPI 1629015227
$2,137.00
in general payments reported to CMS, 2019-2025
23 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $165 · 2021: $18.30 · 2022: $102 · 2023: $235 · 2024: $533 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $445.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $367.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.38 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $117.33 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $107.75 | 2019-2025 | |
| Astellas Pharma US INC | $100.52 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $86.87 | 2025 | |
| Merck Sharp & Dohme LLC | $75.00 | 2019-2020 | |
| Amgen INC. | $73.90 | 2019-2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $71.17 | 2020-2024 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $61.94 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $54.60 | 2019-2024 | Airsupra, Farxiga |
| Baxter Healthcare | $48.05 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $47.47 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.51 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $46.41 | 2025 | Neffy, Grastek, Odactra |
| Insulet Corporation | $41.48 | 2023 | Omnipod |
| Gilead Sciences, INC. | $41.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.03 | 2019-2020 | |
| Eisai INC. | $15.32 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2019 | |
| Abbvie INC. | $14.33 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Partridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.